SBIR Phase II: An Interactive Graphical Application for Next-Generation Surveillance of Hospital-Acquired Infections using Whole Genome Sequencing and Advanced Analytics

SBIR 第二阶段：使用全基因组测序和高级分析进行下一代医院获得性感染监测的交互式图形应用程序

基本信息

批准号：
1830867
负责人：
Susanna Lamers
金额：
$ 73.51万
依托单位：
Bioinfoexperts, LLC
依托单位国家：
美国
项目类别：
Standard Grant
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-15 至 2022-08-31
项目状态：
已结题

来源：
https://www.nsf.gov/awardsearch/showAward?AWD_ID=1830867&HistoricalAwards=false
关键词：
SBIR Phase II Interactive Graphical

项目摘要

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project will be a user-friendly and scalable infection control surveillance software platform using advanced biotech and data analytics for monitoring hospital-acquired infection. There is a significant clinical problem in hospitals, where 1 in 25 people who check in will develop a hospital acquired infection. Currently, hospital infection control practitioners (ICPs) have few analytical tools to identify the source of these infections, which can be deadly and cost the health care industry an estimate of $45 billion year. The innovation under development harnesses advanced epidemiological approaches in an easy-to-use application that will enable ICPs to use bacterial genetics as a means to monitor infectious spread within their system so that their sources can be eliminated.The intellectual merit of this SBIR Phase II proposal is to develop an infection control surveillance software system using whole-genome sequencing of pathogens and advanced data analytics. The innovation addresses the critical lack of accessible genetic analysis applications designed for local infection control surveillance. Hospitals are observing ever increasing rates of antibiotic resistant infections. These are expensive, endanger patients, and are becoming harder to trace as medical care becomes more complex and spread over multiple facilities. Unfortunately, ICPs have few new tools, other than best hygiene practices, to reduce their mounting infection rates. Decades of research has revealed that epidemiological surveillance using genetic analysis provides a robust level of pathogen traceability; however, this knowledge has not been transferred into hospitals where it is critically needed, due to a lack of technical infrastructure and analytical accessibility. In this Phase II project, the goal is to complete the development of a software application that will enable ICPs to easily and accurately process bacterial genetic data in their own offices and generate rich, meaningful and easy to interpret reports concerning bacterial spread in their networks. ICPs will be warned when infection sources relate to each other, suggesting that a deeper investigation is needed. The result is that infection sources, which are currently missed, will be proactively identified and targeted.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）II期项目的更广泛的影响/商业潜力将是一个使用高级生物技术和数据分析的用户友好且可扩展的感染控制监视软件平台，用于监测医院获得的感染。医院存在一个重大的临床问题，其中有25人入住的人会发展出医院的感染。目前，医院感染控制从业人员（ICP）几乎没有分析工具来识别这些感染的来源，这可能是致命的，并且损失了医疗保健行业的估计为450亿美元。开发中的创新在易于使用的应用中利用先进的流行病学方法，该方法将使ICP能够使用细菌遗传学作为监控其系统中传染性传播的一种手段，以便可以消除该SBIR II期建议的智力优点。使用全元素分析的II II期建议的智力功能可以开发出感染监测软件系统。这项创新解决了针对局部感染控制监视的临界遗传分析应用的严重缺乏。医院正在观察到抗生素耐药性感染的速度不断提高。这些是昂贵的危险患者，并且随着医疗服务变得更加复杂并分布在多个设施上，因此变得越来越难。不幸的是，除了最佳卫生习惯以外，ICP几乎没有新工具，可以降低其越来越多的感染率。数十年的研究表明，使用遗传分析的流行病学监测提供了强大的病原体可追溯性水平。但是，由于缺乏技术基础设施和分析可访问性，这些知识尚未转移到需要急需的医院中。在此II阶段项目中，目标是完成软件应用程序的开发，该应用程序将使ICP能够轻松，准确地处理自己的办公室中的细菌遗传数据，并产生丰富，有意义且易于解释有关细菌在其网络中传播的报告。当感染资源相互关联时，将警告ICP，这表明需要进行更深入的调查。结果是，当前错过的感染资源将被主动确定和针对性。该奖项反映了NSF的法定任务，并被认为是值得通过基金会的知识分子优点和更广泛的影响审查标准通过评估来支持的。